Your browser doesn't support javascript.
loading
Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication.
Loft, Anne; Alfaro, Ana Jimena; Schmidt, Søren Fisker; Pedersen, Felix Boel; Terkelsen, Mike Krogh; Puglia, Michele; Chow, Kan Kau; Feuchtinger, Annette; Troullinaki, Maria; Maida, Adriano; Wolff, Gretchen; Sakurai, Minako; Berutti, Riccardo; Ekim Üstünel, Bilgen; Nawroth, Peter; Ravnskjaer, Kim; Diaz, Mauricio Berriel; Blagoev, Blagoy; Herzig, Stephan.
Afiliação
  • Loft A; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Alfaro AJ; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Schmidt SF; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Pedersen FB; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense 5230, Denmark; Center for Functional Genomics and Tissue Plasticity (ATLAS), University of Southern Denmark, Odense 5230, Denmark.
  • Terkelsen MK; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense 5230, Denmark; Center for Functional Genomics and Tissue Plasticity (ATLAS), University of Southern Denmark, Odense 5230, Denmark.
  • Puglia M; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense 5230, Denmark.
  • Chow KK; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Feuchtinger A; Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg 85764, Germany.
  • Troullinaki M; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Maida A; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Wolff G; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Sakurai M; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Berutti R; Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg 85764, Germany.
  • Ekim Üstünel B; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Nawroth P; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; German Center for Diabetes Research (DZD), Neuherberg 85764, Germany; Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg 69120, Germany.
  • Ravnskjaer K; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense 5230, Denmark; Center for Functional Genomics and Tissue Plasticity (ATLAS), University of Southern Denmark, Odense 5230, Denmark.
  • Diaz MB; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
  • Blagoev B; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense 5230, Denmark; Center for Functional Genomics and Tissue Plasticity (ATLAS), University of Southern Denmark, Odense 5230, Denmark.
  • Herzig S; Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg 69120, Germany; Molecular Metabol
Cell Metab ; 33(8): 1685-1700.e9, 2021 08 03.
Article em En | MEDLINE | ID: mdl-34237252
ABSTRACT
Liver fibrosis is a strong predictor of long-term mortality in individuals with metabolic-associated fatty liver disease; yet, the mechanisms underlying the progression from the comparatively benign fatty liver state to advanced non-alcoholic steatohepatitis (NASH) and liver fibrosis are incompletely understood. Using cell-type-resolved genomics, we show that comprehensive alterations in hepatocyte genomic and transcriptional settings during NASH progression, led to a loss of hepatocyte identity. The hepatocyte reprogramming was under tight cooperative control of a network of fibrosis-activated transcription factors, as exemplified by the transcription factor Elf-3 (ELF3) and zinc finger protein GLIS2 (GLIS2). Indeed, ELF3- and GLIS2-controlled fibrosis-dependent hepatokine genes targeting disease-associated hepatic stellate cell gene programs. Thus, interconnected transcription factor networks not only promoted hepatocyte dysfunction but also directed the intra-hepatic crosstalk necessary for NASH and fibrosis progression, implying that molecular "hub-centered" targeting strategies are superior to existing mono-target approaches as currently used in NASH therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Redes Reguladoras de Genes / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Metab Assunto da revista: METABOLISMO Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Redes Reguladoras de Genes / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Metab Assunto da revista: METABOLISMO Ano de publicação: 2021 Tipo de documento: Article